isoxazoles has been researched along with Obesity in 35 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.86) | 18.2507 |
| 2000's | 11 (31.43) | 29.6817 |
| 2010's | 23 (65.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guan, M; Li, N; Song, J; Sun, S; Wang, R; Zhang, J; Zhang, X; Zhao, Z | 1 |
| Ballon, JS; Contreras, I; Freyberg, R; Freyberg, Z; Leibel, RL; Lieberman, JA; Mayer, LE; Pajvani, UB; Rosenbaum, M | 1 |
| Fitch, M; González-Granillo, M; Gustafsson, JÅ; Hellerstein, M; Korach-André, M; Li, X; Parini, P; Pedrelli, M; Savva, C | 1 |
| Ghanizadeh, A; Nikseresht, MS; Sahraian, A | 1 |
| Carta, F; Scozzafava, A; Supuran, CT | 1 |
| Apovian, CM; Aronne, LJ | 2 |
| Gadde, KM | 1 |
| Alphs, L; Bossie, CA; Fu, DJ; Sliwa, JK; Turkoz, I | 1 |
| Iwamura, T; Kainoh, M; Kawai, K; Kumagai, H; Nakaki, J; Nitta, A; Okazaki, S; Sakami, S; Sato, M; Sekiya, Y; Takahashi, T; Yagi, M | 1 |
| Bray, GA; Gadde, KM; Shin, JH; Østbye, T | 1 |
| Helland, A; Spigset, O; Syrstad, VE | 1 |
| Drews, G; Düfer, M; Kähny, V; Krippeit-Drews, P; Peter, A; Schittenhelm, B; Wagner, R | 1 |
| Fujioka, K | 1 |
| Horvath, R; Janszky, J; Komoly, S | 1 |
| Amin, SG; Bisson, WH; Brocker, CN; Desai, D; Gavrilova, O; Gonzalez, FJ; Jiang, C; Krausz, KW; Li, J; Liu, Y; Lv, Y; Patterson, AD; Shi, J; Xie, C | 1 |
| De Simone, G; Di Fiore, A; Supuran, CT | 1 |
| Janszky, J | 1 |
| Bouchaert, E; Caron, S; Derudas, B; Dumont, J; Helleboid-Chapman, A; Kerr-Conte, J; Lucas, A; Pattou, F; Popescu, IR; Staels, B; Vandewalle, B | 1 |
| Arita, E; Auwerx, J; Horai, Y; Houten, SM; Itoh, H; Mataki, C; Morimoto, K; Sato, H; Schoonjans, K; Sugizaki, T; Tanigawara, Y; Watanabe, M | 1 |
| Aher, NG; Cho, H; Kafle, B; Khadka, D; Park, H | 1 |
| Baldelli, F; Cipriani, S; D'Amore, C; Distrutti, E; Fiorucci, S; Mencarelli, A; Palladino, G; Renga, B | 1 |
| Kim, DW; Park, KS; Yoo, MW | 1 |
| Katz, MH | 1 |
| Allison, DB; Bray, GA; Gadde, KM; Kopping, MF; Wagner, HR; Yonish, GM | 1 |
| Franciscy, DM; Gadde, KM; Krishnan, KR; Wagner, HR | 1 |
| Cheskin, LJ; Sidhaye, A | 1 |
| D'Alessio, DA; Guerdjikova, AI; Hudson, JI; Keck, PE; Kotwal, R; Lake, KA; McElroy, SL; Nelson, EB; Welge, JA | 1 |
| Foust, MS; Gadde, KM; Wagner, HR; Yonish, GM | 1 |
| Al-Zaman, Y; Aylwin, S | 1 |
| Bymaster, FP; Cowley, MA; Gadde, KM; Krishnan, RK; Landbloom, RP; McKinney, AA; Sinnayah, P; Tollefson, GD; Wallingford, NM | 1 |
| Matsui, K; Shibata, T; Wakitani, K; Yonemori, F | 1 |
| Kakimoto, K; Shibata, T; Takeuchi, S; Wakitani, K; Yokota, S; Yonemori, F | 1 |
| Inoue, S; Murakami, T; Osaka, T; Yamazaki, Y | 1 |
| Hasegawa, M; Makino, H; Nishimiya, T; Ochi, M; Onuma, H; Osawa, H; Tang, Y | 1 |
7 review(s) available for isoxazoles and Obesity
| Article | Year |
|---|---|
Antiobesity carbonic anhydrase inhibitors: a literature and patent review.
Topics: Animals; Anti-Obesity Agents; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Drug Design; Fructose; Humans; Isoxazoles; Lipogenesis; Mitochondria; Molecular Targeted Therapy; Obesity; Patents as Topic; Topiramate; Zonisamide | 2013 |
Current and emerging medications for overweight or obesity in people with comorbidities.
Topics: Anti-Obesity Agents; Bupropion; Cinnamates; Comorbidity; Cyclohexanes; Diabetes Mellitus; Dyslipidemias; Epoxy Compounds; Humans; Hypertension; Isoxazoles; Obesity; Overweight; Prediabetic State; Sesquiterpenes; Weight Loss; Zonisamide | 2015 |
[ZONISAMIDE: FIRST CHOICE AMONG THE FIRST-LINE ANTIEPILEPTIC DRUGS IN FOCAL EPILEPSY].
Topics: Adolescent; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Carbamazepine; Drug Administration Schedule; Drug Approval; Drug Prescriptions; Electroencephalography; Encephalitis; Epilepsies, Partial; Humans; Hungary; Isoxazoles; Levetiracetam; Magnetic Resonance Imaging; Medication Adherence; Obesity; Phenytoin; Piracetam; Risk Assessment; Risk Factors; Seizures; Stroke; Weight Loss; Young Adult; Zonisamide | 2015 |
Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity.
Topics: Anti-Obesity Agents; Carbonic Anhydrase Inhibitors; Cytosol; Fructose; Humans; Isoxazoles; Mitochondria; Obesity; Topiramate; Zonisamide | 2008 |
[Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases].
Topics: Anticonvulsants; Bipolar Disorder; Calcium Channels, T-Type; Cholinergic Agents; Dopamine Agents; Dyskinesias; Epilepsy; Excitatory Amino Acid Agents; Feeding and Eating Disorders; GABA Agents; Humans; Isoxazoles; Migraine Disorders; Nerve Tissue Proteins; Nervous System Diseases; Neuroprotective Agents; Obesity; Parkinson Disease; Randomized Controlled Trials as Topic; Sodium Channels; Treatment Outcome; Voltage-Gated Sodium Channel beta-2 Subunit; Zonisamide | 2009 |
Pharmacologic treatment of obesity.
Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Fructose; Humans; Isoxazoles; Lactones; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Selective Serotonin Reuptake Inhibitors; Topiramate; Zonisamide | 2006 |
Emerging concepts in the medical and surgical treatment of obesity.
Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Bariatric Surgery; Body Mass Index; Bupropion; Cholecystokinin; Ciliary Neurotrophic Factor; Clinical Trials as Topic; Cyclobutanes; Depression; Diabetes Mellitus, Type 2; Female; Fluoxetine; Fructose; Ghrelin; Humans; Intra-Abdominal Fat; Islet Amyloid Polypeptide; Isoxazoles; Lactones; Leptin; Metabolic Syndrome; Metformin; Obesity; Obesity, Morbid; Orlistat; Oxyntomodulin; Peptide YY; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant; Sertraline; Sleep Apnea, Obstructive; Surgical Procedures, Operative; Topiramate; Zonisamide | 2008 |
8 trial(s) available for isoxazoles and Obesity
| Article | Year |
|---|---|
Pathophysiology of drug induced weight and metabolic effects: findings from an RCT in healthy volunteers treated with olanzapine, iloperidone, or placebo.
Topics: Adolescent; Adult; Antipsychotic Agents; Blood Glucose; Body Weight; Double-Blind Method; Dyslipidemias; Eating; Energy Metabolism; Female; Glucose Tolerance Test; Healthy Volunteers; Humans; Insulin; Insulin Resistance; Isoxazoles; Lipids; Male; Obesity; Olanzapine; Piperidines; Weight Gain; Young Adult | 2018 |
The effect of zonisamide on antipsychotic-associated weight gain in patients with schizophrenia: a randomized, double-blind, placebo-controlled clinical trial.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Double-Blind Method; Female; Follow-Up Studies; Humans; Isoxazoles; Male; Obesity; Schizophrenia; Statistics, Nonparametric; Treatment Outcome; Waist Circumference; Weight Gain; Young Adult; Zonisamide | 2013 |
Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate.
Topics: Adult; Antipsychotic Agents; Blood Glucose; Body Mass Index; Body Weight; Double-Blind Method; Female; Humans; Isoxazoles; Lipids; Male; Middle Aged; Obesity; Paliperidone Palmitate; Palmitates; Schizophrenia; Weight Gain; Young Adult | 2014 |
Weight changes in obese adults 6-months after discontinuation of double-blind zonisamide or placebo treatment.
Topics: Adult; Anti-Obesity Agents; Anticonvulsants; Body Mass Index; Cohort Studies; Combined Modality Therapy; Diet, Reducing; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Isoxazoles; Life Style; Male; Middle Aged; North Carolina; Obesity; Patient Compliance; Patient Education as Topic; Weight Gain; Zonisamide | 2014 |
Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial.
Topics: Adolescent; Adult; Aged; Antioxidants; Body Mass Index; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Isoxazoles; Male; Middle Aged; Obesity; Retrospective Studies; Treatment Outcome; Weight Loss; Young Adult; Zonisamide | 2012 |
Zonisamide for weight loss in obese adults: a randomized controlled trial.
Topics: Adult; Anti-Obesity Agents; Anticonvulsants; Body Mass Index; Caloric Restriction; Combined Modality Therapy; Diet, Reducing; Double-Blind Method; Female; Humans; Isoxazoles; Life Style; Male; Obesity; Patient Education as Topic; Risk Reduction Behavior; Single-Blind Method; Treatment Outcome; Weight Loss; Zonisamide | 2003 |
Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial.
Topics: Adult; Anticonvulsants; Body Mass Index; Bulimia; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Isoxazoles; Male; Middle Aged; Obesity; Weight Loss; Zonisamide | 2006 |
Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study.
Topics: Adult; Analysis of Variance; Anti-Obesity Agents; Bupropion; Drug Therapy, Combination; Female; Humans; Isoxazoles; Obesity; Treatment Outcome; Waist-Hip Ratio; Weight Loss; Zonisamide | 2007 |
20 other study(ies) available for isoxazoles and Obesity
| Article | Year |
|---|---|
Blocking gp130 signaling suppresses autotaxin expression in adipocytes and improves insulin sensitivity in diet-induced obesity.
Topics: 3T3-L1 Cells; Adipocytes; Animals; Cytokine Receptor gp130; Diet; Down-Regulation; Fatty Acids, Nonesterified; Glucose; Hydrazines; Insulin Resistance; Interleukin-6; Isoxazoles; Janus Kinases; Lipolysis; Lysophospholipids; Mice; Obesity; Phosphoric Diester Hydrolases; Propionates; Quinoxalines; Signal Transduction; STAT3 Transcription Factor | 2017 |
ERβ activation in obesity improves whole body metabolism via adipose tissue function and enhanced mitochondria biogenesis.
Topics: Adipose Tissue; Animals; Energy Metabolism; Estrogen Receptor beta; Female; Gene Expression Profiling; Isoxazoles; Ligands; Lipogenesis; Lipolysis; Liver; Mice, Inbred C57BL; Mitochondria; Obesity; Organelle Biogenesis | 2019 |
Zonisamide for weight reduction in obese adults.
Topics: Female; Humans; Isoxazoles; Male; Obesity; Weight Loss | 2013 |
Weight loss treatment in obese adults.
Topics: Female; Humans; Isoxazoles; Male; Obesity; Weight Loss | 2013 |
Weight loss treatment in obese adults--reply.
Topics: Female; Humans; Isoxazoles; Male; Obesity; Weight Loss | 2013 |
HIS-388, a novel orally active and long-acting 11β-hydroxysteroid dehydrogenase type 1 inhibitor, ameliorates insulin sensitivity and glucose intolerance in diet-induced obesity and nongenetic type 2 diabetic murine models.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adamantane; Administration, Oral; Animals; Azepines; Carbenoxolone; Diabetes Mellitus, Experimental; Enzyme Inhibitors; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Resistance; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Microsomes, Liver; Obesity; Pioglitazone; Thiazolidinediones; Triazoles | 2014 |
Prolonged elimination of paliperidone after administration of paliperidone palmitate depot injections.
Topics: Adult; Antipsychotic Agents; Delayed-Action Preparations; Humans; Isoxazoles; Male; Obesity; Paliperidone Palmitate; Palmitates; Pyrimidines; Schizophrenia; Time Factors | 2015 |
Role of FXR in β-cells of lean and obese mice.
Topics: Animals; Chenodeoxycholic Acid; Female; Glucose; Insulin; Insulin Secretion; Insulin-Secreting Cells; Isoxazoles; Male; Mice; Mice, Knockout; Mice, Obese; Obesity; Receptors, Cytoplasmic and Nuclear; Taurochenodeoxycholic Acid | 2015 |
Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction.
Topics: Adolescent; Adult; Aged; Animals; Ceramides; Cholic Acids; Diet, High-Fat; Fatty Liver; Female; Glycine; Humans; Ileum; Insulin Resistance; Intestinal Mucosa; Isoxazoles; Liver; Male; Mice; Middle Aged; Obesity; Receptors, Cytoplasmic and Nuclear; Young Adult | 2015 |
The nuclear receptor FXR is expressed in pancreatic beta-cells and protects human islets from lipotoxicity.
Topics: Animals; Blotting, Western; Cells, Cultured; Humans; In Vitro Techniques; Insulin-Secreting Cells; Islets of Langerhans; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Obesity; Palmitic Acid; Rats; Receptors, Cytoplasmic and Nuclear | 2010 |
Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure.
Topics: 3T3-L1 Cells; Animals; Bile Acids and Salts; Body Weight; Diabetes Mellitus; Dietary Fats; Energy Metabolism; Isoxazoles; Metabolic Syndrome; Mice; Obesity; Receptors, Cytoplasmic and Nuclear | 2011 |
Isoxazol-5(4H)one derivatives as PTP1B inhibitors showing an anti-obesity effect.
Topics: Animals; Anti-Obesity Agents; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Obesity; Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 2011 |
FXR activation improves myocardial fatty acid metabolism in a rodent model of obesity-driven cardiotoxicity.
Topics: Acyl-CoA Oxidase; Animals; Apoptosis; Bile Acids and Salts; Blood Glucose; Cardiovascular Diseases; Chenodeoxycholic Acid; Dyslipidemias; Fibrosis; Hyperinsulinism; Hyperlipidemias; Insulin Resistance; Isoxazoles; Lipid Metabolism; Liver; Myocardium; Obesity; PPAR alpha; Protein Serine-Threonine Kinases; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Risk Factors; RNA, Messenger; Triglycerides | 2013 |
Low serum leptin level is associated with zonisamide-induced weight loss in overweight female epilepsy patients.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Epilepsy; Female; Follow-Up Studies; Humans; Isoxazoles; Leptin; Linear Models; Middle Aged; Obesity; Prospective Studies; Weight Loss; Young Adult; Zonisamide | 2012 |
Zonisamide: no magic bullet.
Topics: Female; Humans; Isoxazoles; Male; Obesity; Weight Loss; Zonisamide | 2012 |
Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats.
Topics: Animals; Anticonvulsants; Appetite Regulation; Benzodiazepines; Biomarkers; Body Weight; Diabetes Mellitus; Female; Hyperglycemia; Hyperphagia; Hypothalamic Area, Lateral; Intracellular Signaling Peptides and Proteins; Isoxazoles; Neurons; Neuropeptides; Nucleus Accumbens; Obesity; Olanzapine; Orexins; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Weight Gain; Zonisamide | 2008 |
JTT-501, a novel oral antidiabetic agent, improves insulin resistance in genetic and non-genetic insulin-resistant models.
Topics: Animals; Blood Glucose; Disease Models, Animal; Glucose; Glucose Clamp Technique; Glucose Tolerance Test; Hyperglycemia; Hypoglycemic Agents; Infusions, Intravenous; Insulin; Insulin Resistance; Isoxazoles; Leptin; Lipids; Male; Obesity; Oxidation-Reduction; Phosphorylation; Proteins; Rats; Rats, Sprague-Dawley; Rats, Zucker; Receptor, Insulin; Triglycerides | 1998 |
Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats.
Topics: Absorptiometry, Photon; Animals; Body Weight; Bone Density; Bone Diseases, Metabolic; Cataract; Chromans; Diabetes Complications; Diabetes Mellitus; Diabetic Nephropathies; Diabetic Neuropathies; Eating; Hypoglycemic Agents; Isoxazoles; Male; Neural Conduction; Obesity; Pancreas; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Thiazoles; Thiazolidinediones; Time Factors; Transcription Factors; Troglitazone | 2000 |
JTT-501, a new oral hypoglycemic agent, reverses hypertriglyceridemia in Zucker fatty and ventromedial hypothalamus-lesioned obese rats.
Topics: Animals; Blood Glucose; Female; Hypertriglyceridemia; Hypoglycemic Agents; Hypothalamus, Middle; Insulin; Isoxazoles; Lipoprotein Lipase; Obesity; Rats; Rats, Wistar; Triglycerides | 2000 |
Adipocyte-specific reduction of phosphodiesterase 3B gene expression and its restoration by JTT-501 in the obese, diabetic KKAy mouse.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adipocytes; Adipose Tissue; Animals; Blood Glucose; Blotting, Western; Cyclic Nucleotide Phosphodiesterases, Type 3; Diabetes Mellitus; Diabetes Mellitus, Experimental; Epididymis; Fatty Acids; Female; Gene Expression Regulation, Enzymologic; Hypoglycemic Agents; Insulin; Insulin Resistance; Isoxazoles; Liver; Male; Mice; Mice, Inbred C57BL; Obesity; RNA, Messenger; Triglycerides | 2001 |